RenovoRx Inc.

RNXT | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.71

+$0.04 (+2.40%)

Sep 22, 2026, 2:02 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

Key Executives

Name	Position
Shaun R. Bagai	Chief Executive Officer, Secretary & Director
Leesa Gentry	Chief Clinical Officer
Mark Voll	CFO & Principal Accounting Officer
Phil Stocton	Vice President of Sales & Market Development
Ramtin Agah	Founder, Executive Chairman & Chief Medical Officer
Robert Strasser	Vice President of Operations and R&D
Ronald Kocak	VP of Finance & Controller
Ryan Witt	Senior Vice President and Head of Corporate Strategy & Partnerships
Tom Kelly	Vice President of Quality & Operations

Latest SEC Filings

Date	Type	Title
Aug 20, 2026	8-K	Current Report
Aug 13, 2026	10-Q	Quarterly Report
Aug 13, 2026	8-K/A	[Amend] Current Report
Aug 12, 2026	8-K	Current Report
Aug 04, 2026	8-K	Current Report
Jul 02, 2026	8-K	Current Report
Jun 30, 2026	S-8	Filing
Jun 30, 2026	8-K	Current Report
Jun 24, 2026	4	Filing
May 21, 2026	4	Filing

View All SEC Filings ➞

RenovoRx Inc.

Country	United States
IPO Date	Aug 25, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	17
CEO	Shaun R. Bagai

Contact Details

4546 El Camino Real Mountain View, California 94040 United States

https://renovorx.com

650 284 4433

Stock Details

Ticker Symbol	RNXT
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001574094
CUSIP Number	75989R107
ISIN Number	US75989R1077
SIC Code	2834